- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04028193
Fat Supplementation on Dumping Syndrome Associated Symptoms (Fat on DS)
November 12, 2022 updated by: Chatzipapa Nikoleta, Technological Educational Institute of Thessaly
The Effect of Fat Supplementation on the Appearance of Symptoms Associated With Dumping Syndrome in Patients Undergone Bariatric Surgery
The purpose of the study is the investigation of the effect of fat supplement on gastric emptying rate and the appearance of symptoms of Dumping Syndrome in patients who have undergone gastrointestinal- duodenal surgery.
Patients who have undergone bariatric surgery have been examined for the presence of the Dumping syndrome, with glucose measurements, the Sigstad's questionnaire and questionnaire of Arts.
Patients diagnosed positive, reiterated the examination process in a second meeting consuming an extra fat supplement.
The data obtained on the different appointments were compared between the two groups in a cross over design.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
25
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: NIKOLETA CHATZIPAPA
- Phone Number: 00306982484394
- Email: nikoletaxatzhpapa@hotmail.com
Study Contact Backup
- Name: DEMETRA HARITOU
- Phone Number: 00306973240203
- Email: dharitou@yahoo.gr
Study Locations
-
-
-
Thessaloniki, Greece, 56533
- Recruiting
- Nikoleta Chatzipapa
-
Contact:
- NIKOLETA CHATZIPAPA
- Email: nikoletaxatzhpapa@hotmail.com
-
Contact:
- DEMETRA HARITOU
- Email: dharitou@yahoo.gr
-
Principal Investigator:
- Demetra Haritou
-
Principal Investigator:
- Nikoleta Chatzipapa
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients with Dumping Syndrome
Exclusion Criteria:
- Patients with diabetes mellitus type 1 and 2, Patients with impaired balance of fluids and electrolytes, Patients on diuretics pills or corticosteroids or hypoglycemic tablets and Insulin.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: Diagnose Dumping after supplement consumption
Carbohydrate ingestion to provoke dumping syndrome related symptoms
|
Carbohydrate Supplement
|
|
Other: Fat supplementation
A high fat supplement was added to the carbohydrate liquid meal that was previously used for diagnosis.
|
Polyunsaturated liquid fat supplement
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Glucose Levels
Time Frame: before the ingestion of the carbohydrate and fat supplement (baseline)
|
Blood glucose measurement
|
before the ingestion of the carbohydrate and fat supplement (baseline)
|
|
Glucose Levels
Time Frame: 30 minutes after the ingestion of the carbohydrate and fat supplement
|
Blood glucose measurement
|
30 minutes after the ingestion of the carbohydrate and fat supplement
|
|
Glucose Levels
Time Frame: 60 minutes after the ingestion of the the carbohydrate and fat supplement
|
Blood glucose measurement
|
60 minutes after the ingestion of the the carbohydrate and fat supplement
|
|
Glucose Levels
Time Frame: 90 minutes after the ingestion of the the carbohydrate and fat supplement
|
Blood glucose measurement
|
90 minutes after the ingestion of the the carbohydrate and fat supplement
|
|
Glucose Levels
Time Frame: 120 minutes after the ingestion of the the carbohydrate and fat supplement
|
Blood glucose measurement
|
120 minutes after the ingestion of the the carbohydrate and fat supplement
|
|
Sigstad's Questionnaire
Time Frame: 1st hour after the ingestion of the supplements
|
Dumping syndrome symptom associated questionnaire
|
1st hour after the ingestion of the supplements
|
|
Sigstad's Questionnaire
Time Frame: 2nd hour after the ingestion of the supplements
|
Dumping syndrome symptom associated questionnaire
|
2nd hour after the ingestion of the supplements
|
|
Arts's Questionnaire
Time Frame: 1st hour after the ingestion of the supplements
|
Dumping syndrome symptom associated questionnaire
|
1st hour after the ingestion of the supplements
|
|
Arts's Questionnaire
Time Frame: 2nd hour after the ingestion of the supplements
|
Dumping syndrome symptom associated questionnaire
|
2nd hour after the ingestion of the supplements
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 12, 2017
Primary Completion (Anticipated)
December 1, 2022
Study Completion (Anticipated)
April 1, 2023
Study Registration Dates
First Submitted
July 15, 2019
First Submitted That Met QC Criteria
July 18, 2019
First Posted (Actual)
July 22, 2019
Study Record Updates
Last Update Posted (Actual)
November 15, 2022
Last Update Submitted That Met QC Criteria
November 12, 2022
Last Verified
November 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 5411069DD0467
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dumping Syndrome
-
Universitaire Ziekenhuizen KU LeuvenCompletedPostoperative Dumping SyndromeBelgium
-
University Hospital, Basel, SwitzerlandCompletedBariatric Surgery | Postprandial Hypoglycemia | Late Dumping SyndromeSwitzerland
-
Radboud University Medical CenterUnknown
-
Universitaire Ziekenhuizen KU LeuvenIpsenCompleted
-
Novartis PharmaceuticalsCompletedDumping SyndromeBelgium, Netherlands, Germany, France, United States
-
Larissa University HospitalRecruitingDumping Syndrome | Gastric SurgeryGreece
-
Samsung Medical CenterRecruitingDumping Syndrome | Esophagectomy | Continous Glucose MeasurementSouth Korea
-
University Hospital, LilleCompleted
-
Cambridge University Hospitals NHS Foundation TrustCompleted
-
University Hospital Inselspital, BerneCompletedDumping Syndrome | Hypoglycemia, ReactiveSwitzerland
Clinical Trials on Resource Energy
-
Larissa University HospitalRecruitingDumping Syndrome | Gastric SurgeryGreece
-
Clínica de GastroenterologiaNestlé Portugal SA; Angelini Pharma Portugal, Unipessoal, LdaCompletedColonoscopy | Bowel PreparationPortugal
-
University GhentFund for Scientific Research, Flanders, Belgium; International Centre for Reproductive...CompletedIntimate Partner ViolenceBelgium
-
University of AlbertaCompleted
-
University of HohenheimCompleted
-
Brigham and Women's HospitalBristol-Myers SquibbActive, not recruitingRheumatoid Arthritis | Systemic Sclerosis | Inflammatory Arthritis | Psoriatic Arthritis | Sjogren's Syndrome | Juvenile Rheumatoid Arthritis | Ankylosing Spondylitis | Undifferentiated Connective Tissue Diseases | Lupus | Sacroiliitis | Sicca Syndrome | Mixed Connective Tissue Disease | Palindromic Arthritis | Enteropathic...United States
-
Seattle Children's HospitalPatient-Centered Outcomes Research Institute; Children's Hospital of PhiladelphiaRecruiting
-
University of NottinghamCompletedEnteral Feeding | Diarrhoea | Nasogastric FeedingUnited Kingdom
-
Children's Hospital of PhiladelphiaCompletedSocial Determinants of Health | Low-income PopulationsUnited States